ELI LILLY AND COMPANY Deferred Tax Liabilities, Leasing Arrangements
ELI LILLY AND COMPANY (LLY) had Deferred Tax Liabilities, Leasing Arrangements of $219.10 million as of 2024-12-31, per its 10-K filed 2025-02-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesLeasingArrangements · last filed 2025-02-19
- 2024-12-31: Deferred Tax Liabilities, Leasing Arrangements $219.10M.
- 2023-12-31: Deferred Tax Liabilities, Leasing Arrangements $237.10M.
- 2022-12-31: Deferred Tax Liabilities, Leasing Arrangements $130.70M.
- 2021-12-31: Deferred Tax Liabilities, Leasing Arrangements $132.60M.
| Period end | Deferred Tax Liabilities, Leasing Arrangements |
|---|---|
| 2024-12-31 | $219.10M 10-K · filed 2025-02-19 |
| 2023-12-31 | $237.10M 10-K · filed 2025-02-19 |
| 2022-12-31 | $130.70M 10-K · filed 2024-02-21 |
| 2021-12-31 | $132.60M 10-K · filed 2023-02-22 |
| 2020-12-31 | $134.30M 10-K · filed 2022-02-23 |
| 2019-12-31 | $124.70M 10-K · filed 2021-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |